Multiple myeloma: evolving genetic events and host interactions

By W. Kuehl, P. Bergsagel. Nature Reviews. Cancer, 2002

855 citations recorded by the source corpus.

Subfields: Genetics, Hematology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/2429538886c90cec893343e1698ebbeb94081a4d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. David M. Sabatini
2. M. Laplante
3. Nathanael S. Gray

In Hematology

1. David M. Sabatini
2. Nathanael S. Gray
3. M. Laplante
4. S. Rajkumar

In Molecular Biology

1. David M. Sabatini
2. M. Laplante
3. Timothy R. Peterson
4. Y. Sancak
5. C. Thoreen
6. S. A. Kang
7. Nathanael S. Gray
8. W. Kuehl

Citations in the corpus

• DEPTOR is an mTOR Inhibitor Whose Frequent Overexpression in Multiple Myeloma Cells Promotes their Survival (2009, background): “Anomalously, this was not the case for MMs, a malignancy of antibody-producing plasma cells (reviewed in Kuehl and Bergsagel, 2002 ), in which the DEPTOR mRNA is overexpressed (Figure 6A, Table S1).”
• Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. (2007, background): “A variety of secondary genetic events, associated with disease progression have been observed and include deletion of chromosome 13, amplification of chromosome 1q, deletion of TP53, activating point mutations of ras, and translocations of c-myc (Kuehl and Bergsagel, 2002).”